Compare A & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | A | KVUE |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8B | 33.7B |
| IPO Year | 1999 | 2023 |
| Metric | A | KVUE |
|---|---|---|
| Price | $118.07 | $17.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $161.47 | $19.45 |
| AVG Volume (30 Days) | 1.5M | ★ 14.9M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | 0.92% | ★ 4.82% |
| EPS Growth | 3.16 | ★ 40.74 |
| EPS | ★ 1.07 | 0.76 |
| Revenue | $4,472,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $8.45 | $4.85 |
| Revenue Next Year | $6.13 | $2.63 |
| P/E Ratio | $109.82 | ★ $22.89 |
| Revenue Growth | ★ 6.43 | N/A |
| 52 Week Low | $106.55 | $14.02 |
| 52 Week High | $160.27 | $25.17 |
| Indicator | A | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 55.21 |
| Support Level | $115.76 | $17.20 |
| Resistance Level | $130.54 | $17.75 |
| Average True Range (ATR) | 3.32 | 0.32 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 54.75 | 84.76 |
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.